Do short-sellers have these three stocks pegged? You be the judge!
News & Analysis: Provectus Pharmaceuticals
Down by double digits in just a few days. Why these 3 health-care stocks were the most horrendous performers this week.
Provectus' roller coaster ride has left investors nauseous.
These five stocks suffered double-digit percentage declines last week.
Four positive clinical updates, a billion-dollar licensing deal, a surprising positive opinion for one company in the EU, and a rough NYSEArca debut for one biopharma are this week's top biotech stories.
Provectus shares tumble after it refutes misleading claims in a blog. Find out what investors should really be paying attention to instead.
Which health-care stocks stood out as the most humongous winners this week? Provectus, Inovio, and United Therapeutics take the honors.